{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:58:33Z","timestamp":1787803113666,"version":"build-2784847793"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceutical Company Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Oxford PharmaGenesis"},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The objective was to investigate the efficacy and safety of soticlestat as adjunctive therapy in participants with complex regional pain syndrome (CRPS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A proof-of-concept phase 2a study, comprising a 15-week randomized, double-blind, placebo-controlled, parallel-group study (part A), and an optional 14-week open-label extension (part B).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty-four participants (median age 44.5\u2009years [range, 18\u201362\u2009years]; 70.8% female) with chronic CRPS were randomized (2:1) to receive oral soticlestat or placebo. Soticlestat dosing started at 100\u2009mg twice daily and was titrated up to 300\u2009mg twice daily. In part B, soticlestat dosing started at 200\u2009mg twice daily and was titrated up or down at the investigator\u2019s discretion. Pain intensity scores using the 11-point Numeric Pain Scale (NPS) were collected daily. The Patient-Reported Outcomes Measurement Information System (PROMIS)-29, Patients\u2019 Global Impression of Change (PGI-C), and CRPS Severity Score (CSS) were completed at screening and weeks 15 and 29.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From baseline to week 15, soticlestat treatment was associated with a mean change in 24-hour pain intensity NPS score (95% confidence interval) of \u20130.75 (\u20131.55, 0.05) vs \u20130.41 (\u20131.41, 0.59) in the placebo group, resulting in a non-significant placebo-adjusted difference of \u20130.34 (\u20131.55, 0.88; P\u2009=\u2009.570). Statistically non-significant numerical changes were observed for the PROMIS-29, PGI-C, and CSS at weeks 15 and 29.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Adjunctive soticlestat treatment did not significantly reduce pain intensity in participants with chronic CRPS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/pm\/pnac198","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T21:33:30Z","timestamp":1671572010000},"page":"872-880","source":"Crossref","is-referenced-by-count":7,"title":["Randomized controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in adults with complex regional pain syndrome"],"prefix":"10.1093","volume":"24","author":[{"given":"Stuart","family":"Ratcliffe","sequence":"first","affiliation":[{"name":"St Pancras Clinical Research, London, EC2Y 8EA, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Arkilo","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited , Cambridge, MA 02139, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8060-2148","authenticated-orcid":false,"given":"Mahnaz","family":"Asgharnejad","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited , Cambridge, MA 02139, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipta","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited , Cambridge, MA 02139, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Norman","family":"Harden","sequence":"additional","affiliation":[{"name":"Departments of Physical Medicine and Rehabilitation and Physical Therapy and Human Movement Science, , Northwestern University Feinberg School of Medicine , Chicago, IL 60611, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"issue":"1-2","key":"2023070519281979500_pnac198-B1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pain.2006.09.008","article-title":"The incidence of complex regional pain syndrome: A population-based study","volume":"129","author":"de Mos","year":"2007","journal-title":"Pain"},{"issue":"1","key":"2023070519281979500_pnac198-B2","first-page":"49","article-title":"Complex regional pain syndrome","volume":"104","author":"Lloyd","year":"2021","journal-title":"Am Fam Physician."},{"issue":"3","key":"2023070519281979500_pnac198-B3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0304-3959(98)00246-2","article-title":"Epidemiology of complex regional pain syndrome: a retrospective chart review of 134 patients","volume":"80","author":"Allen","year":"1999","journal-title":"Pain"},{"issue":"4","key":"2023070519281979500_pnac198-B4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/AJP.0b013e31818ecea5","article-title":"The natural history of complex regional pain syndrome","volume":"25","author":"Schwartzman","year":"2009","journal-title":"Clin J Pain"},{"issue":"4","key":"2023070519281979500_pnac198-B5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1526-4637.2006.00169.x","article-title":"Proposed new diagnostic criteria for complex regional pain syndrome","volume":"8","author":"Harden","year":"2007","journal-title":"Pain Med"},{"issue":"4","key":"2023070519281979500_pnac198-B6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0885-3924(00)00183-4","article-title":"Course of symptoms and quality of life measurement in Complex Regional Pain Syndrome: A pilot survey","volume":"20","author":"Galer","year":"2000","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"2023070519281979500_pnac198-B7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pain.2013.12.017","article-title":"Health-related quality of life in 975 patients with complex regional pain syndrome type 1","volume":"155","author":"van Velzen","year":"2014","journal-title":"Pain"},{"issue":"2","key":"2023070519281979500_pnac198-B8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/pme.12033","article-title":"Complex regional pain syndrome: practical diagnostic and treatment guidelines, 4th edition","volume":"14","author":"Harden","year":"2013","journal-title":"Pain Med"},{"issue":"Suppl 1","key":"2023070519281979500_pnac198-B9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/pm\/pnac046","article-title":"Complex regional pain syndrome: practical diagnostic and treatment guidelines, 5th Edition","volume":"23","author":"Harden","year":"2022","journal-title":"Pain Med"},{"issue":"4","key":"2023070519281979500_pnac198-B10","first-page":"Cd009416","article-title":"Interventions for treating pain and disability in adults with complex regional pain syndrome","volume":"2013","author":"O'Connell","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2023070519281979500_pnac198-B11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11916-018-0667-7","article-title":"Complex regional pain syndrome, current concepts and treatment options","volume":"22","author":"Urits","year":"2018","journal-title":"Curr Pain Headache Rep"},{"issue":"7","key":"2023070519281979500_pnac198-B12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(11)70106-5","article-title":"Clinical features and pathophysiology of complex regional pain syndrome","volume":"10","author":"Marinus","year":"2011","journal-title":"Lancet Neurol"},{"issue":"1-3","key":"2023070519281979500_pnac198-B13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pain.2009.08.015","article-title":"Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study","volume":"147","author":"Schwartzman","year":"2009","journal-title":"Pain"},{"issue":"3","key":"2023070519281979500_pnac198-B14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.pain.2009.06.023","article-title":"Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1","volume":"145","author":"Sigtermans","year":"2009","journal-title":"Pain"},{"issue":"2","key":"2023070519281979500_pnac198-B15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11916-018-0664-x","article-title":"The effect of ketamine infusion in the treatment of complex regional pain syndrome: A systemic review and meta-analysis","volume":"22","author":"Zhao","year":"2018","journal-title":"Curr Pain Headache Rep"},{"issue":"16","key":"2023070519281979500_pnac198-B16","doi-asserted-by":"crossref","first-page":"12228","DOI":"10.1021\/acs.jmedchem.1c00864","article-title":"Discovery of soticlestat, a potent and selective inhibitor for cholesterol 24-hydroxylase (CH24H)","volume":"64","author":"Koike","year":"2021","journal-title":"J Med Chem"},{"issue":"1","key":"2023070519281979500_pnac198-B17","doi-asserted-by":"crossref","first-page":"17081","DOI":"10.1038\/s41598-020-74036-6","article-title":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice","volume":"10","author":"Nishi","year":"2020","journal-title":"Sci Rep"},{"issue":"44","key":"2023070519281979500_pnac198-B18","doi-asserted-by":"crossref","first-page":"17290","DOI":"10.1523\/JNEUROSCI.2619-13.2013","article-title":"The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors","volume":"33","author":"Paul","year":"2013","journal-title":"J Neurosci"},{"issue":"9","key":"2023070519281979500_pnac198-B19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/00001756-200506210-00007","article-title":"24S-hydroxycholesterol induces inflammatory gene expression in primary human neural cells","volume":"16","author":"Alexandrov","year":"2005","journal-title":"Neuroreport"},{"issue":"1-2","key":"2023070519281979500_pnac198-B20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pain.2004.08.001","article-title":"Chronic post-ischemia pain (CPIP): A novel animal model of complex regional pain syndrome-type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in the rat","volume":"112","author":"Coderre","year":"2004","journal-title":"Pain"},{"issue":"6","key":"2023070519281979500_pnac198-B21","first-page":"2899","article-title":"Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers","volume":"88","author":"Wang","year":"2022"},{"issue":"11","key":"2023070519281979500_pnac198-B22","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1111\/bcp.14854","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects","volume":"87","author":"Wang","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2023070519281979500_pnac198-B23","year":"2020"},{"issue":"8","key":"2023070519281979500_pnac198-B24","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/j.pain.0000000000000927","article-title":"A prospective, multisite, international validation of the Complex Regional Pain Syndrome Severity Score","volume":"158","author":"Harden","year":"2017","journal-title":"Pain"},{"issue":"7","key":"2023070519281979500_pnac198-B25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.7326\/M17-0509","article-title":"Low-dose intravenous immunoglobulin treatment for long-standing complex regional pain syndrome: A randomized trial","volume":"167","author":"Goebel","year":"2017","journal-title":"Ann Intern Med"},{"issue":"9","key":"2023070519281979500_pnac198-B26","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1007\/s00586-010-1353-6","article-title":"Outcome measures in chronic low back pain","volume":"19","author":"Maughan","year":"2010","journal-title":"Eur Spine J"},{"issue":"10","key":"2023070519281979500_pnac198-B27","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s11136-021-02925-y","article-title":"Minimal important change (MIC): A conceptual clarification and systematic review of MIC estimates of PROMIS measures","volume":"30","author":"Terwee","year":"2021","journal-title":"Qual Life Res"},{"key":"2023070519281979500_pnac198-B28","doi-asserted-by":"crossref","first-page":"106646","DOI":"10.1016\/j.eplepsyres.2021.106646","article-title":"A phase 1b\/2a study of soticlestat as adjunctive therapy in participants with developmental and\/or epileptic encephalopathies","volume":"174","author":"Halford","year":"2021","journal-title":"Epilepsy Res"},{"key":"2023070519281979500_pnac198-B29","volume-title":"American Epilepsy Society 71st Annual Meeting,","author":"Wagner"},{"issue":"4","key":"2023070519281979500_pnac198-B30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1034\/j.1600-0404.2000.101004262x.\/","article-title":"Neurological findings in complex regional pain syndromes: Analysis of 145 cases","volume":"101","author":"Birklein","year":"2000","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"2023070519281979500_pnac198-B31","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1080\/14656566.2019.1612367","article-title":"Pharmacotherapeutic options for complex regional pain syndrome","volume":"20","author":"Iolascon","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"2023070519281979500_pnac198-B32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ner.12691","article-title":"Prevalence and cost analysis of Complex Regional Pain Syndrome (CRPS): A role for neurostimulation","volume":"21","author":"Elsamadicy","year":"2018","journal-title":"Neuromodulation"},{"issue":"8","key":"2023070519281979500_pnac198-B33","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.pain.2014.05.009","article-title":"Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: An ACTTION study","volume":"155","author":"Farrar","year":"2014","journal-title":"Pain"},{"issue":"3","key":"2023070519281979500_pnac198-B34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neulet.2008.03.081","article-title":"Neuropeptides, neurogenic inflammation and Complex Regional Pain Syndrome (CRPS)","volume":"437","author":"Birklein","year":"2008","journal-title":"Neurosci Lett"},{"issue":"2","key":"2023070519281979500_pnac198-B35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pain.2010.04.030","article-title":"Validation of proposed diagnostic criteria (the \u201cBudapest Criteria\u201d) for Complex Regional Pain Syndrome","volume":"150","author":"Harden","year":"2010","journal-title":"Pain"},{"issue":"6","key":"2023070519281979500_pnac198-B36","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/j.pain.0000000000000866","article-title":"Recommendations for a first Core Outcome Measurement set for complex regional PAin syndrome Clinical sTudies (COMPACT)","volume":"158","author":"Grieve","year":"2017","journal-title":"Pain"},{"issue":"2","key":"2023070519281979500_pnac198-B37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.36076\/ppj.2011\/14\/145","article-title":"A comprehensive review of opioid-induced hyperalgesia","volume":"14","author":"Lee","year":"2011","journal-title":"Pain Physician"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/painmedicine\/advance-article-pdf\/doi\/10.1093\/pm\/pnac198\/48732296\/pnac198.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/24\/7\/872\/50825542\/pnac198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/24\/7\/872\/50825542\/pnac198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T19:47:18Z","timestamp":1688586438000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/24\/7\/872\/6947961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,12,20]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnac198","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,12,20]]}}}